R&D,Bioprocess,Clinical Development,Weekly Roundups,News

Weekly News Round-up – 15/1/21

Proventa International Weekly News 2 years ago By Josh Neil
Proventa International Weekly News

In the news this week, COVID vaccine production continues to advance, with Regeneron signing a new $2.6 billion deal in the US, the J&J one-shot looks set to distribute in March 2021, and two inhaler treatments advance in trials. In other news, GSK announces it could double its blockbusters over the next five years, and Sanofi buys antibody company Kymab for $1.1 billion.

GLAXOSMITHKLINE LOOKS TO DOUBLE BLOCKBUSTERS IN PORTFOLIO REVIVAL – GSK is seeking to revive its product lineup with a host of new blockbusters in the run up to 2026, the company has announced. The new drugs include lung cancer drug Zejula and an anti-COVID antibody treatment, and could see sales of more than $1 billion in the next five years. 

REGENERON SIGNS $2.6 BILLION DEAL ON COVID ANTIBODY SUPPLY – Having previously agreed to supply 300,000 doses of its COVID-19 antibody product to the US, Regeneron has now signed a larger deal for up to 1.25 million doses – reputedly worth around $2.63 billion. Currently Regeneron’s product has been green-lit at a dose of 2,400mg. But should Regeneron receive approval for lower dosages, it expects to fulfil the entire order by June 2021. 

SANOFI BUYS ANTIBODY GIANT KYMAB – Pharma giant Sanofi is set to pay $1.1 billion up-front, plus milestone increments of up to $350 million, to purchase Cambridge-based antibody company Kymab. The deal means Sanofi purchases global rights to KY1005, a fully human monoclonal antibody with a novel mechanism of action. KY1005 can potentially treat a large number of immune-mediated diseases and inflammatory disorders.

In other news: 

R&D

Boehringer and Enara Bio collaborate on novel targeted cancer immunotherapy research

UK company IosBio touts pill as replacement to COVID-19 vaccines 

Clinical

Synairgen’s inhaled COVID-19 formulation enters phase 3

Verona Pharma finishes pilot enrolment for COVID-19 inhaler treatment

Manufacturing

Johnson & Johnson set to begin one-shot COVID vaccine distribution in March 2021

BioNTech increases 2021 COVID vaccine delivery target to 2 billion doses

That’s all for now. See you next week!

Joshua Neil, Editor
Proventa International

More news

RNA Therapeutics: The World’s First mRNA Malaria Vaccine

Malaria represents one of the greatest unmet clinical needs in the world. In the last decade, research has been ongoing to develop effective preventative methods and effective treatment to reduce the risk of severe illness, which typically occurs in children....

2 years ago
R&D,Bioprocess,Clinical Development,Weekly Roundups,News

RNA Therapeutics: The World’s First mRNA Malaria Vaccine

Malaria represents one of the greatest unmet clinical needs in the world. In the last decade, research has been ongoing to develop effective preventative methods and effective treatment to reduce the risk of severe illness, which typically occurs in children....

2 years ago

Raising Representation in Clinical Trials: An Interview with Liz Beatty, Inato

The COVID-19 pandemic created a significant shortage of suitable patients for clinical trials worldwide. Within this crisis was another more serious issue around inclusion and representation, driven by COVID’s disparate effect on certain ethnicities, that spoke to a wider issue...

2 years ago
R&D,Bioprocess,Clinical Development,Weekly Roundups,News

Raising Representation in Clinical Trials: An Interview with Liz Beatty, Inato

The COVID-19 pandemic created a significant shortage of suitable patients for clinical trials worldwide. Within this crisis was another more serious issue around inclusion and representation, driven by COVID’s disparate effect on certain ethnicities, that spoke to a wider issue...

2 years ago

Intrinsically Disordered Proteins – The Implication in Cancer and Potential Drug Targets

Intrinsically disordered proteins (IDPs) are under the limelight in cancer research. While research is continuous in understanding their dynamic structure, their implication in tumour development is becoming increasingly evident. Some of the latest advancements demonstrate how IDPs can be used...

2 years ago
R&D,Bioprocess,Clinical Development,Weekly Roundups,News

Intrinsically Disordered Proteins – The Implication in Cancer and Potential Drug Targets

Intrinsically disordered proteins (IDPs) are under the limelight in cancer research. While research is continuous in understanding their dynamic structure, their implication in tumour development is becoming increasingly evident. Some of the latest advancements demonstrate how IDPs can be used...

2 years ago